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Abstract—The authentic standards 2-(cyclopropanecarboxamido)-N-(4-methoxypyridin-3-yl)isonicotinamide (4a) and 2-
(cyclopropanecarboxamido)-N-(4-(4-methoxyphenyl)pyridin-3-yl)isonicotinamide (7a), and their corresponding precursors 2-
(cyclopropanecarboxamido)-N-(4-hydroxypyridin-3-yl)isonicotinamide (4b) and 2-(cyclopropanecarboxamido)-N-(4-(4-
hydroxyphenyl)pyridin-3-yl)isonicotinamide (7b) were synthesized from methyl 2-aminoisonicotinate and cyclopropanecarbonyl chloride 
with overall chemical yield 47% in three steps, 22% in four steps, 40% in three steps, and 17% in four steps, respectively. The target 
tracers 2-(cyclopropanecarboxamido)-N-(4-[11C]methoxypyridin-3-yl)isonicotinamide ([11C]4a) and 2-(cyclopropanecarboxamido)-N-(4-
(4-[11C]methoxyphenyl)pyridin-3-yl)isonicotinamide ([11C]7a) were prepared from the precursors (4b and 7b) with [11C]CH3OTf through 
O-[11C]methylation and isolated by HPLC combined with SPE in 40-50% radiochemical yield, based on [11C]CO2 and decay corrected to 
end of bombardment (EOB). The radiochemical purity was >99%, and the specific activity (SA) at EOB was 370-1110 GBq/µmol with a 
total synthesis time of ~40-minutes from EOB. 
Keywords: Carbon-11-labeled isonicotinamides; Glycogen synthase kinase-3 (GSK-3); Radiosynthesis; Positron 
emission tomography (PET); Alzheimer’s disease (AD). 
Alzheimer’s disease (AD) is the most common form of 
dementia and affects over 30 million people worldwide, 
and there are no reliable disease-modifying therapies at 
present.1-4 Currently, the cause of AD remains unclear 
and no any effective strategy is approved for preventing, 
curing and slowing the progress of AD.5-7 To discover 
more effective treatments, a reliable diagnostic tool is 
really needed.8 Neuroimaging of AD is one of the most 
active as well as most challenging areas in 
neuroscience.9 Advanced biomedical imaging technique 
positron emission tomography (PET) is a promising 
modality for AD, and significant advances have 
accomplished in this field of molecular imaging.10 The 
development of PET imaging probes for in vivo 
detection of Alzheimer’s brains is critical for early and 
accurate diagnosis and for the successful discovery of 
disease-modifying therapies.11-13 Currently, aggregated 
β-amyloid plaques (Aβ) and tau protein are two major 
biomarkers for AD.14,15 The representative Aβ PET 
tracers are [11C]PIB16 and [18F]Amyvid (formerly 
known as [18F]AV-45),17 as displayed in Figure 1, the 
representative PET tau tracers include [11C]PBB18 and 
[18F]T807 ([18F]AV-1451)19 (Figure 1), and promising 
clinical PET imaging results with these tracers have 
been reported.        
The success and limitations of Aβ imaging and tau 
imaging have spurred efforts worldwide to develop new 
selective PET tracers for different imaging targets, and 
glycogen synthase kinase-3 (GSK-3) has become a 
novel and attractive molecular target for treatment and 
PET imaging of AD.20 The enzyme GSK-3 is a 
serine/threonine protein kinase, which exists as two 
isoforms GSK-3α and GSK-3β. GSK-3 plays an 
important role in a number of diverse cellular processes 
including metabolism, differentiation, proliferation, and 
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apoptosis. Thus, GSK-3 is associated with a variety of 
diseases including AD, type II diabetes, neurological 
disorders, and cancer.1 In our previous work, we and 
other have developed [11C]SB-216763 (GSK-3β/α IC50 
(nM) 34.3/34.3, Figure 1) as a PET GSK-3 imaging 
agent.21,22 However, not very high in vitro binding 
affinity (IC50) of SB-216763 and complicated two-step 
radiosynthesis of [11C]SB-216763 have motivated us to 
develop the new generation of GSK-3 PET probes. 
Recently, a new class of isonicotinamides was 
developed by Bristol-Myers Squibb (BMS) as highly 
selective, brain penetrable, and orally active GSK-3 
inhibitors, and the representative compounds 2-
(cyclopropanecarboxamido)-N-(4-methoxypyridin-3-
yl)isonicotinamide (4a) and 2-
(cyclopropanecarboxamido)-N-(4-(4-
methoxyphenyl)pyridin-3-yl)isonicotinamide (7a) 
showed appreciable inhibitory activity with GSK-3β/α 
IC50 (nM) 3.4/4.5 and 2.1/0.45, respectively.1 In 
addition, both compounds 4a and 7a possess O-methyl 
position amenable to labeling with carbon-11 for one-
step radiosynthesis. Here, we report the synthesis of 
carbon-11-labeled isonicotinamides (Figure 1) as new 
potential PET agents for imaging of GSK-3 enzyme in 
AD.   
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Figure 1. Chemical structure of [11C]PIB, [18F]Amyvid ([18F]AV-45), 
[11C]PBB3, [18F]T807 ([18F]AV-1451), [11C]SB-216763 and carbon-11-
labeled isonicotinamides. 
 
The synthesis of isonicotinamides 4a,b is outlined in 
Scheme 1, according to the literature method1 with 
modifications. Commercial available starting material 
methyl 2-aminoisonicotinate was reacted with 
cyclopropanecarbonyl chloride to afford monoacylation 
intermediate 1 in 88% yield, through changing reaction 
solvent and controlling amount of acid chloride (1.1-1.2 
equivalent), which was different from double acylation 
in literature.1 Subsequent treatment with KOH in 
methanol and water achieved complete conversion to 
acylated acid 2, which upon neutralization with aqueous 
HCl precipitated out as a white solid in 98% yield. The 
acid 2 could directly reacted 3-aminopyridines 3a,b 
under corresponding amide formation conditions or be 
firstly converted to the acid chloride with oxalyl 
chloride then to react with 3-aminopyridines 3a,b, to 
give the product isonicotinamides 4a,b in 55% and 46% 
yield, respectively. 
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Scheme 1. Synthesis of isonicotinamides 4a,b. Reagents, conditions and 
yields: (i) pyridine, 0 °C; 88%. (ii) KOH, MeOH, RT; 98%. (iii) oxalyl 
chloride, DMF (cat.), RT; then 3-aminopyridines 3a,b, DIPEA, RT; 55% 
and 46%.  
 
The synthesis of isonicotinamides 7a,b is shown in 
Scheme 2, according to the literature method23 with 
modifications. The acid 2 reacted with 4-iodopyridin-3-
amine using same procedure as the synthesis of 4a,b to 
obtain an intermediate 5 in 41% yield, which could be 
converted to the product 7a,b by Suzuki coupling with 
aryl boronic acid or ester 6a,b in 63% and 48% yield, 
respectively. 
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Scheme 2. Synthesis of isonicotinamides 7a,b. Reagents, conditions and 
yields: (i) oxalyl chloride, DMF (cat.), 0 °C; then 4-iodopyridin-3-amine, 
DIPEA, 0 °C to RT; 41%. (ii) Na2CO3, Pd(PPh3)4, dioxane, 110 °C; 63% 
and 48%. 
 
Synthesis of carbon-11-labeled isonicotinamides 
[11C]4a and [11C]7a is presented in Scheme 3. 
Isonicotinamides desmethyl precursor 4b or 7b 
underwent O-[11C]methylation24,25 using the reactive 
[11C]methylating agent [11C]methyl triflate 
([11C]CH3OTf)26,27 in acetonitrile at 80 °C under basic 
conditions (2 N NaOH). The product was isolated by 
semi-preparative reverse-phase (RP) high performance 
liquid chromatography (HPLC) with a C-18 column, 
and then concentrated by solid-phase extraction (SPE)28-
 
30 with a disposable C-18 Light Sep-Pak cartridge to 
produce the corresponding pure radiolabeled compound 
[11C]4a or [11C]7a in 40-50%  radiochemical yield, 
decay corrected to end of bombardment (EOB), based 
on [11C]CO2. 
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Scheme 3. Synthesis of carbon-11-labeled isonicotinamides [11C]4a and 
[11C]7a. Reagents, conditions and yields: (i) [11C]CH3OTf, CH3CN, 2 N 
NaOH, 80 °C, 3 min; HPLC-SPE; 40-50%.   
 
The radiosynthesis included three stages: 1) labeling 
reaction; 2) purification; and 3) formulation. We 
employed more reactive [11C]CH3OTf, instead of 
commonly used [11C]methyl iodide ([11C]CH3I),31 in O-
[11C]methylation to improve radiochemical yield of 
[11C]4a and [11C]7a. We used an Eckert & Ziegler 
Modular Lab C-11 Methyl Iodide/Triflate module to 
produce [11C]methylating agent either [11C]CH3OTf or 
[11C]CH3I ([11C]CH3Br passed through a NaI column). 
The direct comparison between [11C]CH3OTf and 
[11C]CH3I confirmed this result. The labeling reaction 
was conducted using a V-vial method. Addition of 
aqueous NaHCO3 to quench the radiolabeling reaction 
and to dilute the radiolabeling mixture prior to the 
injection onto the semi-preparative HPLC column for 
purification gave better separation of [11C]4a or [11C]7a 
from its pyridinyl hydroxyl  precursor 4b or phenyl 
hydroxyl precursor 7b. We used Sep-Pak trap/release 
method instead of rotatory evaporation for formulation 
to improve the chemical purity of radiolabeled products 
[11C]4a and [11C]7a. In addition, a C18 Light Sep-Pak 
to replace a C18 Plus Sep-Pak allowed final product 
formulation with ≤5% ethanol.32 Overall, it took ~40 
min for synthesis, purification and dose formulation.     
 
The radiosynthesis was performed in a home-built 
automated multi-purpose [11C]-radiosynthesis 
module.33-35 This radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. In addition, 
the module is designed to allow in-process measurement 
of [11C]-tracer specific activity (SA, GBq/µmol at EOB) 
using a radiation detector at the outlet of the HPLC-
portion of the system. For the reported syntheses, 
product SA was in a range of 370-1110 GBq/µmol at 
EOB. The factors that affect the EOB SA significantly 
to lead to such a wide range from 370 to 1110 
GBq/µmol are mainly from two parts: (1) carrier from 
the [11C]-target, and (2) carrier from the [11C]-
radiosynthesis unit.36,37 We have optimized the [11C] gas 
irradiation target system and the [11C]-radiosynthesis 
unit to eliminate 12C carrier-added as much as possible 
and to reach the high end of the SA. To help produce 
high SA [11C]CO2, we usually do 10-minute target pre-
burn for 2-3 times, with the same beam current, prior to 
the actual production run. These pre-burn warm up the 
cyclotron target and eliminate significant amount of 12C 
carrier in the cyclotron’s [11C] gas target. Our Eckert & 
Ziegler Modular Lab C-11 Methyl Iodide/Triflate 
module produces [11C]CH3OTf, convenient gas phase 
bromination of [11C]methane, and production of 
[11C]CH3OTf. This ‘dry’ method, using Br2 to generate 
a [11C]CH3Br intermediate, differs from other ‘dry’ 
method using I2 and ‘wet’ method using LiAlH4 and HI, 
and seems to help minimize introduction of additional 
12C carrier after [11C]CO2 production.27 To further help 
produce high SA [11C]CH3OTf, we usually do 2 ‘test 
loop’ procedures when we set up the module for the 
actual [11C]CH3OTf production run and 1 actual 
[11C]CH3OTf production run before we do 
[11C]methylation labeling reaction. These procedures 
avoid any leak in the module to introduce additional 12C 
carrier and eliminate significant amount of original 12C 
carrier accumulated in the [11C]CH3OTf production 
system. Therefore, the SA of our [11C]-tracers is 
significantly improved. At the end of synthesis (EOS), 
the SA of [11C]-tracer was determined again by 
analytical HPLC,38 calculated, decay corrected to EOB, 
and based on [11C]CO2, which was in agreement with 
the ‘on line’ determined value. In each our [11C]-tracer 
production, if semi-preparative HPLC was used for 
purification, then the SA of [11C]-tracer was assessed by 
both semi-preparative HPLC (during synthesis) and 
analytical HPLC (EOS); if SPE was used for 
purification, then the SA of [11C]-tracer was only 
measured by analytical HPLC at EOS.25                
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.38 The chemical purity 
of the precursors and reference standard was >90%. The 
radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through γ-ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracer was >90% determined by reversed-phase HPLC 
through UV flow detector.   
 
 
The experimental details and characterization data for 
compounds 1, 2, 4a,b, 5, and 7a,b for the tracers 
[11C]4a and [11C]7a are given.39  
 
In summary, synthetic routes with moderate to high 
yields have been developed to produce isonicotinamide 
precursors and reference standards, and carbon-11-
labeled isonicotinamides. The radiosynthesis employed 
[11C]CH3OTf for O-[11C]methylation at the pyridinyl 
hydroxyl or phenyl hydroxyl position of the desmethyl 
precursor, followed by product purification and 
isolation using a semi-preparative RP HPLC combined 
with SPE. The carbon-11-labeled isonicotinamides were 
obtained in high radiochemical yield, radiochemical 
purity and chemical purity, with a reasonably short 
overall synthesis time, and high specific activity. This 
will facilitate studies to evaluate carbon-11-labeled 
isonicotinamides as new potential PET agents for 
imaging of GSK-3 enzyme in AD.   
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(2): KOH (14.52 g, 0.26 mol) was added into the 
solution of compound 1 (16.2 g, 73.4 mmol) in 
methanol (200 mL) and water (8 mL). The reaction 
mixture was stirred at room temperature (RT) for 6 h, 
then it was evaporated under reduced pressure. The 
residue was neutralized with 2 N aqueous HCl. The 
resulting precipitate was filtered, and dried to give a 
white solid product 2 (14.8 g, 98%). Rf = 0.18 (1:9 
MeOH/CH2Cl2), mp 277-279 °C. 1H NMR (DMSO-
d6): δ 0.82-0.83 (m, 4H, 2 × CH2), 2.00-2.05 (m, 1H, 
CH), 7.48 (d, J = 5.0 Hz, 1H, Ar-H), 8.45 (d, J = 5.0 
Hz, 1H, Ar-H), 8.56 (s, 1H, CONH), 10.99 (1H, OH). 
MS (ESI): 207 ([M+H]+, 100%); MS (ESI): 205 ([M-
H]-, 15%). 
(d). 2-(Cyclopropanecarboxamido)-N-(4-
methoxypyridin-3-yl)isonicotinamide (4a): To a 250 
mL flask was added compound 2 (206 mg, 1.0 mmol) 
in CH2Cl2 (20 mL) to give a white suspension. After 
cooling to 0 °C, oxalyl chloride (0.3 g) and DMF (2 
drops) were added. The mixture was stirred at 0 °C for 
1 h, then the mixture was evaporated in vacuo. A 
solution of 4-methoxypyridin-3-amine (3a, 124 mg, 
1.0 mmol) in CH2Cl2 (5 mL) was added into above 
mixture at 0 °C, followed by N,N-
diisopropylethylamine (DIPEA, 260 mg, 2.0 mmol). 
After stirring at RT for 2 h, the reaction mixture was 
concentrated under reduced pressure to give a tan oil. 
 
The residue was purified by column chromatography 
on silica gel with eluent (3:97 MeOH/CH2Cl2) to give 
a white solid product 4a (164 mg, 55%). Rf = 0.69 (1:9 
MeOH/CH2Cl2), mp 209-211 °C. 1H NMR (CDCl3): δ 
0.93-0.97 (m, 2H, CH2), 1.12-1.15 (m, 2H, CH2), 
1.58-1.63 (m 1H, CH), 3.98 (s, 3H, OCH3), 6.86 (d, J 
= 5.5 Hz, 1H, Ar-H), 7.54 (dd, J = 1.0, 5.0 Hz, 1H, 
Ar-H), 8.30 (s, 1H, Ar-H), 8.35 (d, J = 5.5 Hz, 1H, Ar-
H), 8.43 (d, J = 5.0 Hz, 1H, Ar-H), 8.44 (s, 1H, Ar-H), 
8.62 (s, 1H, NH), 9.53 (s, 1H, NH). MS (ESI): 313 
([M+H]+, 100%); MS (ESI): 311 ([M-H]-, 3%). 
(e). 2-(Cyclopropanecarboxamido)-N-(4-
hydroxypyridin-3-yl)isonicotinamide(4b): Compound 
4b was prepared using the same procedure as 
described for the synthesis of 4a by substituting 4-
hydroxypyridin-3-amine (3b) for 3a as a white solid, 
yield 46%. Rf = 0.58 (1:9 MeOH/CH2Cl2), mp 307-
309 °C. 1H NMR (DMSO-d6): δ 0.83-0.89 (m, 4H, 2 × 
CH2), 2.02-2.08 (m 1H, CH), 6.32 (d, J = 4.5 Hz, 1H, 
Ar-H), 7.48 (dd, J = 1.5, 6.0 Hz, 1H, Ar-H), 7.73 (d, J 
= 8.0 Hz, 1H, Ar-H), 8.49 (dd, J = 0.5, 7.0  Hz, 1H, 
Ar-H), 8.54 (d, J = 1.0 Hz, 1H, Ar-H), 8.76 (s, 1H, Ar-
H), 9.43 (s, 1H, NH), 11.04 (s, 1H, NH), 11.68 (s, 1H, 
OH). 13C NMR (DMSO-d6): δ 8.31, 14.72, 111.18, 
113.33, 116.77, 125.50, 128.41, 136.64, 143.37, 
149.48, 153.47, 163.43, 170.58, 173.46. MS (ESI): 
299 ([M+H]+, 70%); MS (ESI): 297 ([M-H]-, 17%). 
HRMS (ESI) calcd for C15H15N4O3, 299.1144 
([M+H]+); found 299.1137. 
(f). 2-(Cyclopropanecarboxamido)-N-(4-iodopyridin-
3-yl)isonicotinamide (5): Compound 5 was prepared 
from compound 2 with 4-iodopyridin-3-amine using 
the same procedure as described for the synthesis of 
4a as a yellow solid, yield 41%. Rf = 0.70 (1:9 
MeOH/CH2Cl2), mp 156-158 °C. 1H NMR (DMSO-
d6): δ 0.81-0.85 (m, 4H, 2 × CH2), 2.02-2.08 (m, 1H, 
CH), 7.58 (d, J = 5.0 Hz, 1H, Ar-H), 8.07 (d, J = 5.0 
Hz, 1H, Ar-H), 8.12 (d, J = 5.0 Hz, 1H, Ar-H), 8.48 (s, 
1H, Ar-H), 8.52 (d, J = 5.0 Hz, 1H, Ar-H), 8.60 (s, 
1H, Ar-H), 10.55 (s, 1H, NH), 11.01 (s, 1H, NH). MS 
(ESI): 409 ([M+H]+, 100%); MS (ESI): 407 ([M-H]-, 
100%).  
(g). 2-(Cyclopropanecarboxamido)-N-(4-(4-
methoxyphenyl)pyridin-3-yl)isonicotinamide (7a): To 
a suspension of compound 5 (82 mg, 0.2 mmol), (4-
methoxyphenyl)boronic acid (6a, 46 mg, 0.3 mmol), 
and Na2CO3 (53 mg, 0.5 mmol) in dioxane (50 mL) 
was added tetrakis(triphenylphosphine)palladium(0) 
(23 mg, 0.02 mmol). The reaction mixture was 
subsequently heated at 110 °C for 15 h. After the 
reaction was cooled down, it was filtered through 
Celite, washed with dioxane, and concentrated in 
vacuo. The resultant residue was purified by column 
chromatography on silica gel with eluent (2:98 
MeOH/CH2Cl2) to give a white solid product 7a (49 
mg, 63%). Rf = 0.40 (1:19 MeOH/CH2Cl2), mp 170-
172 °C. 1H NMR (CDCl3): δ 0.91-0.95 (m, 2H, CH2), 
1.09-1.13 (m, 2H, CH2), 1.55-1.59 (m, 1H, CH), 3.88 
(s, 3H, OCH3), 7.08 (dd, J = 2.0, 7.0 Hz, 2H, Ph-H), 
7.23 (d, J = 5.0 Hz, 1H, Ar-H), 7.38 (dd, J = 2.0, 7.0 
Hz, 2H, Ph-H), 7.45 (dd, J = 1.5, 5.0 Hz, 1H, Ar-H), 
8.16 (s, 1H, Ar-H), 8.37 (d, J = 5.5 Hz, 1H, Ar-H), 
8.38 (s, 1H, Ar-H), 8.41 (s, 1H, NH), 8.47 (d, J = 5.0 
Hz, 1H, Ar-H), 9.59 (s, 1H, NH); 1H NMR (DMSO-
d6): δ  0.83-0.88 (m, 4H, 2 × CH2), 2.05-2.11 (m, 1H, 
CH), 3.80 (s, 3H, OCH3), 7.03 (d, J = 7.5 Hz, 2H, Ph-
H), 7.43 (d, J = 5.0 Hz, 1H, Ar-H), 7.47 (d, J = 5.0 Hz, 
1H, Ar-H), 7.49 (d, J = 7.5 Hz, 2H, Ph-H), 8.48 (s, 
2H, Ar-H), 8.55 (d, J = 6.0 Hz, 1H, Ar-H), 8.63 (s, 
1H, Ar-H), 10.37 (s, 1H, NH), 11.00 (s, 1H, NH). MS 
(ESI): 389 ([M+H]+, 100%); MS (ESI): 387 ([M-H]-, 
40%). 
(h). 2-(Cyclopropanecarboxamido)-N-(4-(4-
hydroxyphenyl)pyridin-3-yl)isonicotinamide (7b): 
Compound 7b was prepared using the same procedure 
as described for the synthesis of 7a by substituting (4-
hydroxyphenyl)boronic acid (6b) for 6a as a light blue 
solid, yield 48%. Rf = 0.35 (1:16 MeOH/CH2Cl2), mp 
163-165 °C. 1H NMR (DMSO-d6): δ 0.80-0.86 (m, 
4H, 2 × CH2), 2.00-2.05 (m, 1H, CH), 6.80 (d, J = 
10.5 Hz, 2H, Ph-H), 7.34 (d, J = 10.5 Hz, 2H, Ph-H), 
7.40 (s, 1H, Ar-H), 7.41 (s, 1H, Ar-H), 8.44 (d, J = 6.5 
Hz, 1H, Ar-H), 8.47 (s, 1H, Ar-H), 9.49 (d, J = 6.5 Hz, 
1H, Ar-H), 8.56 (s, 1H, Ar-H), 9.66 (s, 1H, OH), 
10.30 (s, 1H, NH), 10.95 (s, 1H, NH). 13C NMR 
(DMSO-d6): δ 7.73, 14.18, 30.62, 111.54, 115.49, 
116.61, 124.11, 126.83, 129.49, 130.68, 143.35, 
145.46, 147.86, 148.47, 149.47, 152.74, 157.82, 
164.90, 172.73. MS (ESI): 375 ([M+H]+, 100%); MS 
(ESI): 373 ([M-H]-, 80%). HRMS (ESI) calcd for 
C21H19N4O3, 375.1457 ([M+H]+); found 375.1451.  
(i) 2-(cyclopropanecarboxamido)-N-(4-
[11C]methoxypyridin-3-yl)isonicotinamide ([11C]4a) 
and 2-(cyclopropanecarboxamido)-N-(4-(4-
[11C]methoxyphenyl)pyridin-3-yl)isonicotinamide 
([11C]7a): [11C]CO2 was produced by the 14N(p,α)11C 
nuclear reaction in the small volume (9.5 cm3) 
aluminum gas target provided with the Siemens RDS-
111 Eclipse cyclotron. The target gas consisted of 1% 
oxygen in nitrogen purchased as a specialty gas from 
Praxair, Indianapolis, IN. Typical irradiations used for 
the development were 58 µA beam current and 15 min 
on target. The production run produced approximately 
25.9 GBq of [11C]CO2 at EOB. The desmethyl 
precursor 4b or 7b (0.1-0.3 mg) was dissolved in 
CH3CN (300 µL). To this solution was added aqueous 
NaOH (2 N, 2 µL). The mixture was transferred to a 
small reaction vial. No-carrier-added (high specific 
activity) [11C]CH3OTf that was produced by the gas-
phase production method27 within 12 min from 
[11C]CO2 through [11C]CH4 and [11C]CH3Br with 
silver triflate (AgOTf) column was passed into the 
reaction vial at RT until radioactivity reached a 
maximum (2 min), and then the reaction vial was 
isolated and heated at 80 °C for 3 min. The contents of 
the reaction vial were diluted with aqueous NaHCO3 
(0.1 M, 1 mL). The reaction vial was connected to a 3-
mL HPLC injection loop. The labeled product mixture 
 
solution was injected onto the semi-preparative HPLC 
column for purification. The product fraction was 
collected in a recovery vial containing 30 mL water. 
The diluted tracer solution was then passed through a 
C-18 Sep-Pak Light cartridge, and washed with water 
(3 × 10 mL). The cartridge was eluted with EtOH (3 × 
0.4 mL) to release the labeled product, followed by 
saline (10-11 mL). The eluted product was then 
sterile-filtered through a Millex-FG 0.2 µm membrane 
into a sterile vial. Total radioactivity was assayed and 
total volume (10-11 mL) was noted for tracer dose 
dispensing. The overall synthesis time including 
HPLC-SPE purification and reformulation was ~40 
min from EOB. The same procedure was used to 
prepare the target tracers [11C]4a and [11C]7a from 
their corresponding precursors 4b and 7b. Retention 
times in the analytical HPLC system were: tR 4b = 
4.60 min, tR 4a = 6.68 min, tR [11C]4a = 6.73 min; and 
tR 7b = 3.23 min, tR 7a = 5.02 min, tR [11C]7a = 5.12 
min. Retention times in the preparative HPLC system 
were: tR 4b = 7.70 min, tR 4a = 10.58 min, tR [11C]4a = 
10.65 min; and tR 7b = 4.56 min, tR 7a = 6.85 min, tR 
[11C]7a = 6.93 min. 
 
 
